Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis
The emerging standard of care for patients with inoperable pancreatic cancer is a combination of cytotoxic drugs gemcitabine and Abraxane, but patient response remains moderate. Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response. Little is known about how sequential dual targeting of tumor tissue tension and vasculature before chemotherapy can affect tumor response. We used intravital imaging to assess how transient manipulation of the tumor tissue, or "priming," using the pharmaceutical Rho kinase inhibitor Fasudil affects response to chemotherapy. Intravital Forster resonance energy transfer imaging of a cyclin-dependent kinase 1 biosensor to monitor the efficacy of cytotoxic drugs revealed that priming improves pancreatic cancer response to gemcitabine/Abraxane at both primary and secondary sites. Transient priming also sensitized cells to shear stress and impaired colonization efficiency and fibrotic niche remodeling within the liver, three important features of cancer spread. Last, we demonstrate a graded response to priming in stratified patient-derived tumors, indicating that fine-tuned tissue manipulation before chemotherapy may offer opportunities in both primary and metastatic targeting of pancreatic cancer.
|ISBN||1946-6242 (Electronic) 1946-6234 (Linking)|
|Authors||Vennin, C.; Chin, V. T.; Warren, S. C.; Lucas, M. C.; Herrmann, D.; Magenau, A.; Melenec, P.; Walters, S. N.; Del Monte-Nieto, G.; Conway, J. R.; Nobis, M.; Allam, A. H.; McCloy, R. A.; Currey, N.; Pinese, M.; Boulghourjian, A.; Zaratzian, A.; Adam, A. A.; Heu, C.; Nagrial, A. M.; Chou, A.; Steinmann, A.; Drury, A.; Froio, D.; Giry-Laterriere, M.; Harris, N. L.; Phan, T.; Jain, R.; Weninger, W.; McGhee, E. J.; Whan, R.; Johns, A. L.; Samra, J. S.; Chantrill, L.; Gill, A. J.; Kohonen-Corish, M.; Harvey, R. P.; Biankin, A. V.; Australian Pancreatic Cancer Genome, Initiative; Evans, T. R.; Anderson, K. I.; Grey, S. T.; Ormandy, C. J.; Gallego-Ortega, D.; Wang, Y.; Samuel, M. S.; Sansom, O. J.; Burgess, A.; Cox, T. R.; Morton, J. P.; Pajic, M.; Timpson, P.|
|Responsible Garvan Author||Prof Paul Timpson|
|Publisher Name||Science Translational Medicine|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/28381539|